Xilio Therapeutics, Inc., also known by its stock exchange name, XLO, is a leading biotechnology company renowned for its development of potent, tumor-selective immuno-oncology therapies for cancer patients. The company's key approach towards cancer treatment marks a significant paradigm shift in the field of oncology. Xilio's main objective is to revolutionize the cancer treatment landscape by introducing therapies that specifically target and eradicate tumors without harm to healthy tissue, thereby dramatically improving patient quality of life and survival rates.
Based in the vibrant biotechnology and biomedical research hub of Waltham, Massachusetts, Xilio Therapeutics was launched in June 2016. The company has since developed highly efficient and ingenious methodologies centered on activating some of the immune system's most potent tools to detect and destroy cancer cells.
One of Xilio's key pipeline therapies is XTX101, a fully human monoclonal antibody designed to overcome the immunosuppressive tumor microenvironment and boost the immune system's ability to fight cancer. The other, XTX201, targets the tumor neovasculature, disrupting the tumor's blood supply and enhancing the effectiveness of other therapies by improving drug delivery to the tumor. These innovative therapies are the result of the company's proprietary technology platform that creates highly selective agents acting only within the tumor microenvironment.
Xilio Therapeutics is focused on running efficient clinical trials and seeking regulatory approval for its therapies to establish new standards in cancer treatment. Guided by a leadership team with a wealth of experience in drug discovery, clinical development, and company-building in the biotech sector, Xilio aims to bring transformative therapies to the millions of cancer patients around the world.
Xilio Therapeutics' shared vision of improving patient lives and its dedication to precision oncology continue to be vital facets driving the company's overall success and distinct recognition in the field of biotechnology. The robust pipeline, innovative technology, and tireless dedication of Xilio Therapeutics equips them to advance the fight against cancer, acting as a beacon of hope for many affected by this chronic disease.